FI954351A - Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina - Google Patents

Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina Download PDF

Info

Publication number
FI954351A
FI954351A FI954351A FI954351A FI954351A FI 954351 A FI954351 A FI 954351A FI 954351 A FI954351 A FI 954351A FI 954351 A FI954351 A FI 954351A FI 954351 A FI954351 A FI 954351A
Authority
FI
Finland
Prior art keywords
alkyl
group
phenyl
pct
hydrogen atom
Prior art date
Application number
FI954351A
Other languages
English (en)
Swedish (sv)
Other versions
FI954351A0 (fi
Inventor
Michael John Grimmin
Paul Raymond Beckett
Mark Hampton Davis
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939305348A external-priority patent/GB9305348D0/en
Priority claimed from GB939320360A external-priority patent/GB9320360D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of FI954351A0 publication Critical patent/FI954351A0/fi
Publication of FI954351A publication Critical patent/FI954351A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FI954351A 1993-03-16 1995-09-15 Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina FI954351A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939305348A GB9305348D0 (en) 1993-03-16 1993-03-16 Hydroxamic acid derivatives as metalloproteinase inhibitors
GB939320360A GB9320360D0 (en) 1993-10-02 1993-10-02 Hydroxamic acid derivatives as metalloproteinase inhibitors
PCT/GB1994/000495 WO1994021625A1 (en) 1993-03-16 1994-03-14 Hydroxamic acid derivatives as metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
FI954351A0 FI954351A0 (fi) 1995-09-15
FI954351A true FI954351A (fi) 1995-09-15

Family

ID=26302598

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954351A FI954351A (fi) 1993-03-16 1995-09-15 Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina

Country Status (12)

Country Link
US (1) US5652262A (fi)
EP (1) EP0689538B1 (fi)
JP (1) JPH08508027A (fi)
AT (1) ATE169621T1 (fi)
AU (1) AU671724B2 (fi)
CA (1) CA2158352A1 (fi)
DE (1) DE69412469T2 (fi)
FI (1) FI954351A (fi)
GB (1) GB2290543B (fi)
NO (1) NO953652D0 (fi)
NZ (1) NZ262447A (fi)
WO (1) WO1994021625A1 (fi)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
GB9502858D0 (en) * 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
AU5002196A (en) * 1995-03-28 1996-10-16 Novo Nordisk A/S Immunosuppressive agents
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
WO1997003966A1 (en) * 1995-07-19 1997-02-06 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
NZ322553A (en) 1995-11-23 1998-12-23 British Biotech Pharm Metalloproteinase inhibitors
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
PL191366B1 (pl) 1996-09-10 2006-05-31 Vernalis Oxford Ltd Zastosowanie pochodnych kwasu hydroksamowego, pochodne kwasu hydroksamowego oraz kompozycje farmaceutyczne je zawierające
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
JP2002534440A (ja) * 1999-01-13 2002-10-15 ヨマー、ファルマカ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング 感染症の治療のための３−イソキサゾリジノンおよびヒドロキシルアミン酸の使用
GB9901863D0 (en) * 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
KR100799192B1 (ko) 2000-07-19 2008-01-31 미쯔비시 웰 파마 가부시키가이샤 히드록삼산계 설폰산 유도체 및 그의 의약 용도
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
WO2004101537A1 (en) * 2003-05-17 2004-11-25 British Biotech Pharmaceuticals Ltd Metalloproteinase inhibitors
EP1660661A2 (en) 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DE69108529T2 (de) * 1990-12-03 1995-11-30 Celltech Therapeutics Ltd Peptidylderivate.
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives

Also Published As

Publication number Publication date
NO953652L (no) 1995-09-15
US5652262A (en) 1997-07-29
AU6213194A (en) 1994-10-11
DE69412469T2 (de) 1999-02-04
GB2290543B (en) 1996-05-22
WO1994021625A1 (en) 1994-09-29
FI954351A0 (fi) 1995-09-15
CA2158352A1 (en) 1994-09-29
ATE169621T1 (de) 1998-08-15
NZ262447A (en) 1996-07-26
NO953652D0 (no) 1995-09-15
JPH08508027A (ja) 1996-08-27
GB2290543A (en) 1996-01-03
EP0689538A1 (en) 1996-01-03
GB9517704D0 (en) 1995-11-01
EP0689538B1 (en) 1998-08-12
AU671724B2 (en) 1996-09-05
DE69412469D1 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
GB2290543B (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
DK96691A (da) Hydroxamsyrebaserede collagenaseinhibitorer
KR927003624A (ko) 화합물
ES2063334T3 (es) Inhibidores de la colagenasa basados en el acido hidroxamico.
YU32100A (sh) Derivati hidrosamske kiseline kao inhibitori matrične metaloproteaze (mmp)
DE60014851D1 (de) Anti-imflammtorische indolderivate
DK0895988T3 (da) Arylsulfonylaminohydroxamsyrederivater
ATE192036T1 (de) Vorrichtung für die vaginale verabreichung von tamoxifen und dessen analogen
DK1295871T3 (da) Vitamin D-derivater med et 22-oxa- eller 22-thiaatom, en C17-sidekæde substitueret med en syre-, ester- eller amid-gruppe og en 16(17)-dobbeltbinding
DE69723258T2 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
EP1252890A4 (en) MEDICINAL AND PREVENTIVE AGENTS FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE COMPOUNDS
NO305165B1 (no) 1-Arylcykloalkylsulfider, -sulfoksyder og -sulfoner, farmas°ytiske preparater og anvendelse derav
AU6454196A (en) Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
MX9709275A (es) Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas.
CO4780024A1 (es) Nuevos derivados del acido hidroxamico utiles para el tratamiento de enfermedades relacionadas con la degradacion del tejido conectivo